Phase III
Kala Pharma, is about to release some big news that will move this little company in a big way.
AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients.
An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.
Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.
Merck’s Keytruda came up short in a pivotal Phase III trial as a second-line treatment for patients with advanced gastricadenocarcinoma or GEJ adenocarcinoma.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
PRESS RELEASES